Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New markers for predicting the efficacy of pemetrexed combined with platinum in the treatment of non-small cell lung cancer and its application

A technology of non-small cell lung cancer and pemetrexed, which is applied in the field of preparing and predicting the efficacy of pemetrexed combined with platinum in the treatment of non-small cell lung cancer

Active Publication Date: 2020-08-04
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no clinically accurate prediction of platinum-based combination regimens (especially, pemetrexed combined with platinum (cisplatin / carboplatin)) before chemotherapy in the treatment of non-small cell lung cancer (especially, lung cancer). Adenocarcinoma) Molecular markers of curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New markers for predicting the efficacy of pemetrexed combined with platinum in the treatment of non-small cell lung cancer and its application
  • New markers for predicting the efficacy of pemetrexed combined with platinum in the treatment of non-small cell lung cancer and its application
  • New markers for predicting the efficacy of pemetrexed combined with platinum in the treatment of non-small cell lung cancer and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0040] 1. Experimental method

[0041] 1. Case information

[0042] In this study, a total of 389 patients with advanced (IIIB or IV) lung adenocarcinoma diagnosed by pathology, cytology, and imaging were included in the first chest department of Peking University Cancer Hospital from September 2014 to December 2016. These patients were treated with pemetrexed combined with platinum (cisplatin / carboplatin) chemotherapy in the first line. Among them, 21 patients did not complete two cycles of chemotherapy due to toxic side effects or EGFR or ALK gene mutations were found during chemotherapy, and 24 patients did not collect pre-chemotherapy serum. In the end, we collected a total of 354 eligible pre-chemotherapy serum samples , for metabolomics detection (see figure 1 ).

[0043] 2. Serum treatment

[0044] The serum samples collected from patients in this study were strictly collected, processed and stored in a uniform way: the patients used yellow blood collection tubes co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses novel markers for predicting the efficacy of pemetrexed-platinum combined treatment on non-small cell lung cancer and its application. Specifically, the invention provides a set of the markers for predicting the efficacy of pemetrexed-platinum combined treatment on non-small cell lung cancer and its use in a product for predicting the efficacy of pemetrexed-platinum combined treatment on non-small cell lung cancer. The markers comprise hypotaurine, uridine, dodecanoyl carnitine, choline, dimethyl glycine, nicotinamide and hexadecanoyl carnitine. The markers and a modelwith the markers can predict the efficacy of the chemotherapy scheme before the patient undergoes chemotherapy and has sensitivity of 90.8% and specificity of 79.5%.

Description

technical field [0001] The invention belongs to the field of biomedicine, more specifically, the invention relates to a new marker for predicting the curative effect of pemetrexed combined with platinum (cisplatin / carboplatin) in the treatment of non-small cell lung cancer (especially lung adenocarcinoma) and Use of them in preparing products for predicting the curative effect of pemetrexed combined with platinum (cisplatin / carboplatin) in the treatment of non-small cell lung cancer (especially lung adenocarcinoma). Background technique [0002] Lung cancer is a common malignant tumor and the type of cancer that causes the largest number of deaths every year. Among them, 65-70% of non-small cell lung cancer patients are stage IIIB / IV when they are diagnosed, and chemotherapy is the main treatment. The standard first-line chemotherapy for non-small cell lung cancer is a platinum-based combination regimen (pemetrexed, gemcitabine, paclitaxel, docetaxel, vinorelbine, etc. comb...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/50
CPCG01N30/02
Inventor 王洁田艳华王志杰段建春白桦赫捷高树庚万蕊
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com